127 related articles for article (PubMed ID: 10225716)
1. LDL-Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy.
Koll RA
Ther Apher; 1998 May; 2(2):142-6. PubMed ID: 10225716
[TBL] [Abstract][Full Text] [Related]
2. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
3. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis].
Thiery J; Seidel D
Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888
[TBL] [Abstract][Full Text] [Related]
4. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies.
Richter WO; Jacob BG; Ritter MM; Sühler K; Vierneisel K; Schwandt P
Metabolism; 1993 Jul; 42(7):888-94. PubMed ID: 8345799
[TBL] [Abstract][Full Text] [Related]
5. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins.
Koll RA
Ther Apher; 1998 May; 2(2):147-52. PubMed ID: 10225717
[TBL] [Abstract][Full Text] [Related]
6. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
7. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation.
Richter WO; Donner MG; Schwandt P
Ther Apher; 1999 Aug; 3(3):203-8. PubMed ID: 10427616
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term effects on serum lipoproteins by three different techniques of apheresis.
Richter WO; Donner MG; Schwandt P
Artif Organs; 1996 Apr; 20(4):311-7. PubMed ID: 8860712
[TBL] [Abstract][Full Text] [Related]
9. [Heparin-induced extracorporeal LDL precipitation (HELP) in therapy refractory hypercholesterolemia and coronary heart disease: effect on clinical and morphological regression of coronary sclerosis].
Schuff-Werner P
Z Kardiol; 1997; 86 Suppl 1():57-64. PubMed ID: 9173722
[TBL] [Abstract][Full Text] [Related]
10. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods].
Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M
Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal treatment of familial hypercholesterolemia with monoclonal antibodies to low-density lipoprotein.
Wingard RL; Lee WO; Hakim RM
Am J Kidney Dis; 1991 Nov; 18(5):559-65. PubMed ID: 1951335
[TBL] [Abstract][Full Text] [Related]
12. Weekly treatment of diet/drug-resistant hypercholesterolemia with the heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) system by selective plasma low-density lipoprotein removal.
Lane DM; McConathy WJ; Laughlin LO; Comp PC; von Albertini B; Gibson SM; Bricker LA; Kozlovskis P; Dorrier C
Am J Cardiol; 1993 Apr; 71(10):816-22. PubMed ID: 8456760
[TBL] [Abstract][Full Text] [Related]
13. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
Jansen M; Gabriel H; Banyai S; Pidlich J; Weidinger F; Hörl WH; Derfler K
Wien Klin Wochenschr; 1996; 108(14):425-31. PubMed ID: 8784984
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Olbricht CJ; Schoeppe E
Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
[TBL] [Abstract][Full Text] [Related]
15. Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins.
Knisel W; Pfohl M; Müller M; Besenthal I; di Nicuolo A; Voelker W; Risler T; Eggstein M
Clin Investig; 1994 Sep; 72(9):660-8. PubMed ID: 7849443
[TBL] [Abstract][Full Text] [Related]
16. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Julius U; Metzler W; Pietzsch J; Fassbender T; Klingel R
Int J Artif Organs; 2002 Dec; 25(12):1180-8. PubMed ID: 12518963
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption.
Schulzeck P; Olbricht CJ; Koch KM
Clin Investig; 1992 Feb; 70(2):99-104. PubMed ID: 1600346
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein apheresis: clinical results with different methods.
Bambauer R
Artif Organs; 2002 Feb; 26(2):133-9. PubMed ID: 11879241
[TBL] [Abstract][Full Text] [Related]
20. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption.
Julius U; Tselmin S; Fischer S; Passauer J; Bornstein SR
Atheroscler Suppl; 2009 Dec; 10(5):12-6. PubMed ID: 20129367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
